India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

Over a hundred companies, including Swiggy and Reliance Power, will announce quarterly earnings. The Indian stock market ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

ICICI Pru Regular Savings Fund (G) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-M) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-Q) 6.13 62,263 0.19 ...

Mumbai, Vashi (Maharashtra) [India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL ... quality active pharmaceutical ingredients (APIs) and intermediates for life-transforming treatments ...

Zydus Lifesciences Limited (Formerly known as ... Conducting trials in India, where there are real-life situations of disease exposure, is critical to determining the effectiveness of IDRIs ...

EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.

Total Operating Expense 2,061.20 1,952.34 1,687.09 1,679.60 ...

Bonus Apr 05, 2010 Apr 06, 2010 Feb 25, 2010 Bonus Ratio: 1 share(s) for every 2 shares held Bonus Aug 30, 2006 Aug 31, 2006 Apr 28, 2006 Bonus Ratio: 1 share(s) for every 1 shares held Zydus ...